The role of mood in irritable bowel syndrome symptom severity and the quality of life

2015 ◽  
Vol 78 (6) ◽  
pp. 618
Author(s):  
S. Pletikosic ◽  
M. Tkalcic ◽  
G. Hauser
2016 ◽  
Vol 25 (2) ◽  
pp. 151-157 ◽  
Author(s):  
Piero Portincasa ◽  
Leonilde Bonfrate ◽  
Maria Scribano ◽  
Anna Kohn ◽  
Nicola Caporaso ◽  
...  

Background & Aims: Irritable Bowel Syndrome (IBS) patients still require effective treatment. The anti-inflammatory property of curcumin and the antispasmodic and carminative effect of fennel suggests that combination of these nutraceutical compounds would be useful in functional bowel disorders including IBS. We assessed the efficacy and tolerability of a combination of curcumin and fennel essential oil (CU-FEO) in IBS symptoms relief. Methods: 121 patients with mild-to-moderate symptoms of IBS defined by an Irritable Bowel Syndrome- symptom severity score (IBS-SSS) 100-300 and abdominal pain score 30-70 on a 100 mm Visual Analogue Scale (VAS), were randomly assigned to CU-FEO or placebo (2 capsules b.d. for 30 days). Primary endpoint was the mean decrease of IBS-SSS at the end of the treatment corrected for the mean baseline score (relative decrease). The impact of the treatment on quality of life was assessed through IBS-QoL questionnaire. Results: CU-FEO was safe, well-tolerated and induced symptom relief in patients with IBS; a significant decrease in the mean relative IBS-SSS was observed after 30 days of treatment (50.05 ± 28.85% vs 26.12 ± 30.62%, P<0.001). This result matched the reduction of abdominal pain and all the other symptoms of IBS-SSS. The percentage of symptom-free patients was significantly higher in the CU-FEO than in the placebo group (25.9% vs. 6.8%, P = 0.005). All domains of IBS-QoL improved consistently. Conclusion: CU-FEO significantly improved symptoms and quality of life in IBS patients over 30 days. Abbreviations: AEs: adverse events; CU-FEO: Curcumin-Fennel Essential Oil; GI: gastrointestinal; IBS: irritable bowel syndrome; IBS-D: irritable bowel syndrome-diarrhea; IBS-C: irritable bowel syndrome-constipation; IBS-SSS: Irritable Bowel Syndrome – symptom severity score; NF-kB: nuclear factor-κB; QoL: quality of life; UC: ulcerative colitis; VAS, Visual Analogue Scale.


2019 ◽  
Vol 156 (6) ◽  
pp. S-584
Author(s):  
Karen Anne O’Laco ◽  
Colleen H. Parker ◽  
Swapna Mahurkar-Joshi ◽  
Wendy Shih ◽  
Elizabeth J. Videlock ◽  
...  

2020 ◽  
Vol 79 (OCE2) ◽  
Author(s):  
Claire Williams ◽  
Elizabeth Williams ◽  
Bernard Corde

AbstractIrritable Bowel Syndrome (IBS) is a chronic and debilitating functional disorder of the gastrointestinal tract with serious and detrimental impacts on quality of life. Its aetiology is largely unknown, and the identification of effective management strategies remains far from complete. Research suggests that people with IBS have a high prevalence of vitamin D deficiency, which may impact on symptom severity and quality of life.A double-blind, placebo-controlled, 2-arm, parallel-design study is underway to investigate the effect of a 12 week, 3,000IU vitamin D p.d. supplementation on symptom severity and quality of life in participants with a clinical diagnosis of IBS. This report assesses whether relationships exist between vitamin D status, IBS severity and quality of life in the baseline (cross-sectional) data.Eighty males and females with a clinical diagnosis of IBS were recruited in phase I of the trial in January-April 2018. Mixed-type IBS and constipation-predominant IBS were the more frequent subtypes (36% and 33%), while diarrhoea-predominant had a lower prevalence (23%). More females (n = 65) than males (n = 15) were recruited to the study which reflects the reported greater prevalence of IBS in women. Baseline serum 25(OH)D levels in participants were classified as deficient 23.1% (n = 18) (< 30nmol/L), insufficient 37.2% (n = 29) (31–49 nmol/L) and sufficient 39.7% (n = 31) (> 50 nmol/L) respectively. The sample median for serum vitamin D at baseline was 42.2 (± 28.3) nmol/L. Quality of Life was significantly associated with two IBS sub-symptoms: pain (p = 0.037, r = 0.233) and distension severity (p = 0.009, r = 0.291). Neither Quality of Life, nor IBS symptom severity score, correlated with vitamin D status in the sample.This study found no relationship between baseline vitamin D status and symptom severity or quality of life in this subsample. Two publications report vitamin D intervention improves quality of life in participants with IBS. It is possible that the unusual homogeneity of these studies enabled identification of these relationships.These initial observations agree with previous reports of widespread vitamin D insufficiency in people with IBS. Analysis of full trial outcomes (July 2019) will determine whether vitamin D supplementation is beneficial for either symptoms severity or quality of life in people with IBS.


2014 ◽  
Vol 146 (5) ◽  
pp. S-537 ◽  
Author(s):  
Juan S. Lasa ◽  
Melisa T. Senderovsky ◽  
Ignacio Fanjul ◽  
Guillermo Dima ◽  
Angel D. Peralta ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document